Dynamic changes of serum hbv pgrna levels in patients with chronic hepatitis B treated with entecavir or peg-interferon

被引：1
|
作者：
Yu, Xiaoqi [1 ]
Yu, Demin [1 ]
Chen, Peizhan [2 ]
Gong, Qiming [3 ]
Zhang, Xinxin [1 ,2 ]
机构：
[1] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Res Lab Clin Virol, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp North, Translat Med Res Ctr, Shanghai, Peoples R China
[3] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Infect Dis, Shanghai, Peoples R China
来源：
JOURNAL OF HEPATOLOGY | 2019年 / 70卷 / 01期
关键词：
D O I：
10.1016/S0618-8278(19)30963-6
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
FRI-218
引用
收藏
页码：E490 / E490
页数：1
相关论文
共 50 条
  • [31] SYSTEMATIC PSYCHIATRIC INTERVENTION IN CHRONIC HEPATITIS C PATIENTS TREATED BY PEG-INTERFERON A2B AND RIBAVIRIN: RANDOMIZED MULTICENTER PROSPECTIVE STUDY
    Guillemard, C.
    Cognard, C.
    Bretagne, A. -L.
    Elfadel, S.
    Even, C.
    Beaujard, E.
    Collet, T.
    Lion, L.
    Toudic, J. -P
    Cohen, D.
    Ollivier-Hourmand, I.
    Chastang, F.
    Dao, T.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S222 - S222
  • [32] Serum HBV RNA is a Predictor of the Genetic Resistant Mutations with Entecavir Treatment in Chronic Hepatitis B Patients
    Zhang, Xiaxia
    Luo, Hao
    Xi, Hongli
    Chen, Jianhong
    Wu, Chihong
    Lu, Haiying
    Huo, Na
    Xu, Xiaoyuan
    HEPATOLOGY, 2017, 66 : 513A - 513A
  • [33] Dynamic changes of liver stiffness predict histological reverse of liver fibrosis in chronic hepatitis B patients treated with entecavir
    Kong, Yuanyuan
    Wu, Xiaoning
    Sun, Yameng
    Feng, Bo
    Mao, Yimin
    Jiang, Wei
    Lu, Lungen
    Chen, Yongpeng
    Sung, Jihong
    Liu, Xueen
    Cheng, Jilin
    Zhou, Jialing
    Wang, Lin
    Ou, Xiaojuan
    Zhang, Hui
    Jia, Jihong
    You, Hong
    HEPATOLOGY, 2016, 64 : 892A - 893A
  • [34] Comparative analysis of Peg-Interferon alpha-2b and Lamivudine in the treatment of chronic hepatitis B patients: Preliminary results
    Koliouskas, D
    Sidiropoulos, I
    Masmanidou, M
    Dokas, S
    Ziakas, A
    JOURNAL OF HEPATOLOGY, 2002, 36 : 237 - 238
  • [35] PEG-Interferon alfa2b plus ribavirin treatment in chronic hepatitis C
    Müller, T
    MONATSSCHRIFT KINDERHEILKUNDE, 2005, 153 (12) : 1192 - 1192
  • [36] Evaluation of treatment of chronic hepatitis B with peg-interferon in a major tertiary hospital in Western Australia
    Muwanwella, N.
    Kontorinis, N.
    Tarquinio, L.
    Flexman, J.
    Nazareth, S.
    Cheng, W.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2011, 26 : 106 - 106
  • [37] Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B
    Liem, Kin Seng
    van Campenhout, Margo J. H.
    Xie, Qing
    Brouwer, Willem Pieter
    Chi, Heng
    Qi, Xun
    Chen, Liang
    Tabak, Fehmi
    Hansen, Bettina E.
    Janssen, Harry L. A.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 49 (04) : 448 - 456
  • [38] Editorial: the durability of seroconversion of hepatitis B e antigen in the treatment of chronic hepatitis B with PEG-interferon alfa-2a
    Wei, M. T.
    Nguyen, M. H.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (11) : 1556 - 1557
  • [39] LIVER FIBROSIS ASSESSED BY TRANSIENT ELASTOGRAPHY PREDICTS RESPONSE IN CHRONIC HEPATITIS C INFECTED PATIENTS TREATED WITH PEG-INTERFERON AND RIBAVIRIN
    Nkhoma, A. N. S.
    Sheridan, D. A.
    Price, D. A.
    Schmid, M. L.
    Miller, C.
    Baxter, K.
    Bassendine, M. F.
    McPherson, S.
    GUT, 2011, 60 : A8 - A9
  • [40] Effects of PEG-interferon alpha plus ribavirin on tryptophan metabolism in patients with chronic hepatitis C
    Comai, Stefano
    Cavalletto, Luisa
    Chemello, Liliana
    Bernardinello, Elisabetta
    Ragazzi, Eugenio
    Costa, Carlo Virgilio Luigi
    Bertazzo, Antonella
    PHARMACOLOGICAL RESEARCH, 2011, 63 (01) : 85 - 92
12345